News

TechNews: Biotechniques January 2017 issue features Dr. Xiaobo WangBiotechniques January 2017 issue features Dr. Xiaobo Wang, Chief Technology Officer at ACEA Biosciences, in the Tech News article – Big Labs and Tiny Instruments. Dr. Wang who helped develop the high performance NovoCyte benchtop flow cytometer, discussed that the adoption of smaller footprint flow cytometer has been robust and that researchers now have the opportunity to reap the benefits ... Read More
ACEA Biosciences Announces Winners of its Travel AwardSan Diego-based biotechnology company awards funding to researchers in the fields of cardiotoxicity and prostate cancer drug discovery. ACEA Biosciences, a privately owned biotechnology company that develops cutting edge instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy scientists who will be presenting research using ACEA Biosciences’ technology at scientific conferences. Highlighting the broad applicability of ACEA’s xCELLigence ... Read More
Monitoring the Formation and Removal of Biofilms From Clinically Relevant Pathogens in Real-TimeSpanish scientists demonstrate that the growth and destruction of medically important bacterial biofilms can be quantitatively monitored in real-time using the xCELLigence technology from ACEA Biosciences. A large percentage of bacterial species are capable of growing on biotic and abiotic surfaces. Within these surfaced-adhered communities secreted signaling molecules are used to coordinate gene expression across the entire colony, thereby promoting ... Read More
WEBINAR – Flow Cytometry: Emerging Instrumentation and Application Trends | Wed, Feb 15, 2017Join us for our webinar on Wednesday, February 15, 2017 at 11 AM EST / 8 AM PST / 4 PM GMT. Flow cytometry remains an essential tool for cell analysis. Although often relegated to specialized core facilities, flow cytometry instruments are in fact becoming increasingly commonplace in life science labs. In this special webinar, viewers will have the chance to learn about recent developments in ... Read More
Using Cell Signaling Activity, Rather Than Biomarkers, to Determine the Optimal Therapeutic Regimen for Breast Cancer PatientsUsing ACEA Bioscience instruments, scientists at the University of Minnesota demonstrated that a functional assay of patient derived tumor cells may be a key to personalized breast cancer therapy. The clinical classification of breast cancers is largely based upon the levels at which the patient’s cancerous cells express estrogen receptor and human epidermal growth factor receptor 2 (HER2), as determined ... Read More
ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 ConferenceNovel EGFR tyrosine kinase inhibitor AC0010 displays high efficacy, tolerability, and safety in phase I/II clinical trials. ACEA Biosciences, Inc. presented today updated efficacy and safety data from its phase I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, at the World Conference on Lung Cancer (WCLC) 2016 in Vienna, Austria. The purpose of the trial ... Read More
ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be PresentedClinical trial results for novel EGFR inhibitor AC0010 will be presented December 7th at World Conference on Lung Cancer. ACEA Biosciences, Inc. announced today that it will be presenting updated efficacy and safety data from its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. “We look forward ... Read More
ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical OfficerFormer Vice President and Head of the Oncology Business Unit at Jiangsu Hengrui Medicine assumes position as Chief Medical Officer at ACEA Biosciences.   ACEA Biosciences Inc. (ACEA), a privately owned biotechnology company focused on pioneering cell analysis instrumentation as well as the discovery and development of novel pharmaceuticals for the treatment of chronic diseases, today announced that Dr. Li ... Read More
Monitoring in Real Time the Formation and Removal of Biofilms From Clinically Relevant PathogensSpanish scientists demonstrate that the growth and destruction of medically important bacterial biofilms can be quantitatively monitored in real-time using the xCELLigence® technology from ACEA Biosciences. In addition to living in a free-floating “planktonic” state within aqueous environments, bacteria can also colonize solid surfaces present at liquid-solid and air-solid interfaces. Within these microenvironments the bacteria “speak” to each other via ... Read More
xCELLigence Instruments From ACEA Biosciences Honored With “Premier Cell Analysis Instrument” Award for 2016For their ability to quantitatively monitor – in a label-free manner – cell number, morphology, and adhesion strength for a broad array of applications, ACEA’s line of real-time cell analyzers has been awarded top honors from Corporate Vision Magazine. Book-ended by molecular analyses and live animal studies, cell-based assays are an indispensable tool for both basic and applied biological research. ... Read More
Scientists At University Hospital In Basel Demonstrate Practical Step Towards Personalizing Cancer TherapyCancer consists of >100 distinct diseases that manifest in ~200 cell types with diverse genetic/mutational etiologies. For the clinician this complexity is compounded by the fact that a single disease phenotype can result from multiple genotypes, each of which requires a unique approach to treatment (estrogen dependent/independent breast cancer being a primary example). This complexity is necessitating a shift away ... Read More
ACEA Biosciences Launches NovoCyte® Yellow (561nm) Laser SystemsWith the addition of a 561nm laser to its NovoCyte cytometers, ACEA Biosciences expands its product configuration capabilities. The two NovoCyte yellow laser system models (NovoCyte 3000 VYB and 3000 RYB) now give customers the ability to excite yellow and green fluorophores of conjugated antibodies, increases instrument sensitivity, and expands NovoCyte’s capacity for the simultaneous detection of multiple fluorescent proteins. ... Read More
Study of Anthracycline-Induced Cardiotoxicity Using xCELLigence® Cardio Instrument Earns Top HonorsFor her investigations into the mechanisms by which angiotensin signaling modulators reduce anthracycline-induced cardiotoxicity, Kim Rockley – a graduate student in Dr. Jason Gill’s lab within the Division of Pharmacy of the School of Medicine, Pharmacy and Healthy at Durham University (UK) – wins 1st place for the junior investigator poster competition at the 2016 Safety Pharmacology Society (SPS) meeting ... Read More
Cancer Immunotherapy Webinar by Dr. Nabil Ahmed on October 20, 2016 (8:00 AM PST)Join us for our Cancer Immunotherapy-focused Webinar with Dr. Nabil Ahmed of Baylor College of Medicine on Thursday, October 20, 2016 (8:00 AM PST – 11:00 AM EST – 4:00 PM GMT). We are looking forward to Dr. Ahmed sharing his groundbreaking data in the cancer immunotherapy field. Sensitive yet Realistic Assessment of CAR T Cell Killing Capacity against Solid Tumors ... Read More
Researcher at the Free University of Brussels in Belgium Receives the 2016 xCELLigence Research Grant from ACEA BiosciencesWorldwide nearly 10 million new cases of mycobacterium tuberculosis (TB) are diagnosed each year, leading to 1.5 million deaths. Despite many decades of TB research, an effective vaccine for this scourge has remained elusive. This is due, in part, to the complexity of TB’s interactions with the host immune system. Most individuals develop an appropriate immune response to TB infection ... Read More
Researchers at Baylor College of Medicine Publish Paper that Demonstrate that CAR-T Cells with Dual Antigen Specificity Display Improved Efficacy Against GlioblastomaEven when they are composed of the same types of cells, tumors located in different regions of a person’s body can behave differently owing to differences in the tumor microenvironment, such as neighboring cells that suppress/dampen the immune response. Additionally, the cells within a single tumor can display considerable heterogeneity due to mutations. It is becoming increasingly clear that these ... Read More
Studying Viruses in Real-TimeDetermining virus titers and tracking virus growth via traditional cytopathic effect assays is labor intensive and produces only endpoint data.  In an effort to establish a more efficient and information rich means of analyzing the effect of the antiviral drug acyclovir on equine herepesvirues, Dr. Stephane Pronost and colleagues at LABÉO Frank Duncombe in France utilized the xCELLigence RTCA technology. ... Read More
ACEA Biosciences Hosts UCSD Postdocs for Exposure to Industry Program  On Thursday June 23, 2016 ACEA Biosciences hosted postdoctoral fellows from UC San Diego’s Exposure to Industry Program (EIP), providing them with insight into the culture, career opportunities, and professional networking of the biotech and pharmaceutical industry. By visiting multiple companies each year, the EIP helps UCSD postdocs within the physical and biological sciences expand their understanding of career ... Read More
ACEA Biosciences Introduces an Immunotherapy Kit for Monitoring and Quantifying the Potency of B Cell KillingLabel-Free Immune Cell Mediated Killing Kinetics and Potency Analysis in Real-Time   ACEA Biosciences, a pioneer in the development of high performance cell analysis platforms including the xCELLigence® Real-Time Cell Analyzer (RTCA) instruments and NovoCyte® flow cytometers, is introducing an immunotherapy kit for in vitro monitoring and quantification of effector-mediated B cell killing. This kit enables continuous real-time monitoring of B ... Read More
ACEA Biosciences Brings Together Leaders in Cancer and Immunotherapy ResearchWith the goal of highlighting recent breakthroughs and emerging trends in cancer and immunotherapy research, ACEA Biosciences hosted its 4th annual symposium last week (April 15-16, 2016) in New Orleans, Louisiana.  Consistent with ACEA’s ambition of promoting cross-discipline dialog and collaboration amongst researchers, the 50+ attendees represented biotechs, big pharma, government, academia, and contract service providers. Dr. David Roberts, Senior ... Read More
Winter 2016 Research Travel Award WinnerACEA Biosciences would like to congratulate Dr. Farah Sheikh, an associate professor in the Department of Medicine at the University of California San Diego, for winning the ACEA Research Travel Award for Winter 2016. Visit our award website to learn more about this program. Dr. Sheikh is awarded for her research using patient-derived induced pluripotent stem cells (iPSCs) to model the disease arrhythmogenic right ... Read More
Fall 2015 Research Travel Award WinnerWe would like to congratulate James Murray, a doctoral student under Dr. James Murphy in the Mitochondrial Biology & Radiation Research Centre at the Institute of Technology Sligo (Ireland), for winning the ACEA Research Travel Award for Fall 2015. Visit our award website to learn more about this program. James Murray is awarded for his research on novel anticancer drug hybrids, wherein two chemotherapeutic ... Read More
Summer 2015 Research Travel Award WinnersWe would like to congratulate Hannah Yong, a doctoral student in the Perinatal Medicine Pregnancy Research Centre at The Royal Women’s Hospital (Australia), and Canan Schumann (Pharm.D.), a doctoral student in the Department of Pharmaceutical Sciences at Oregon State University (USA), for winning the ACEA Research Travel Award for Summer 2015. Visit our award website to learn more about this program. Ms. Yong is awarded ... Read More
Using Cellular Impedance to Tackle ParasitesThe frustration of staring down a microscope to count the number of times a worm wiggles has inspired an innovative test that could help win the war against human parasites. James Cook University (JCU) researchers and American colleagues from ACEA Biosciences and George Washington University have developed the xWORM test which is a fast and accurate way of measuring whether ... Read More
ACEA Biosciences, Inc. Awards the 2015 iCELLigence Research Grant to Christian OwusuOctober 15, 2015, SAN DIEGO, California – ACEA Biosciences, Inc. (ACEA) has awarded Christian Owusu, a Ph.D. candidate at the Wellcome Trust Sanger Institute and the University of Cambridge, the 2015 iCELLigence Research Grant for his proposal entitled “Host-parasite interactions during schistosomiasis infection: a study from the host and the parasite perspective”. Schistosomiasis, also known as snail fever, is a ... Read More
ACEA Biosciences Announces the Successful Completion of 30 Million USD in Venture FundingACEA Biosciences looks to its future with investments from Lilly Asia Ventures and Qiming Venture Partners. ACEA Biosciences, Inc., a privately held drug discovery and scientific instrumentation company, announced today that it has closed a new round of venture funding in the amount of $30 million. The funding was provided by Lilly Asia Ventures and Qiming Venture Partners. Over the ... Read More
ACEA Biosciences, Inc. Welcomes Lincoln C. MuirFOR IMMEDIATE RELEASE March 16, 2015 SAN DIEGO, California – ACEA Biosciences, Inc., a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research, is pleased to announce Lincoln C. Muir as National Sales Director for the United States. Lincoln Muir is a 25 year veteran of the Life Sciences Industry where ... Read More
ACEA Supports Young Cancer Researchers with the iCELLigence Innovative Research GrantFOR IMMEDIATE RELEASE February 20, 2014   San Diego, CA – To further support cancer research progression, ACEA has installed their RTCA-iCELLigence systems in the laboratories of two young cancer researchers: Dr. Melissa L. Fishel, Assistant Professor at Indiana University (USA) and Dr. Isabelle Plante, and Assistant Professor at INRS-Institut Armand-Frappier (Canada). ACEA’s Innovative Research Grant is awarded every 6 ... Read More
Michael Honeysett Appointed as Vice President of Global CommercializationFOR IMMEDIATE RELEASE February 2, 2015 SAN DIEGO, California – ACEA Biosciences, Inc., a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research, is pleased to announce Michael Honeysett as Vice President of Global Commercialization. Mike Honeysett is a seasoned executive in the life science cellular analysis industry. He has created ... Read More
ACEA Biosciences and Hurel® Corporation Announce Joint Marketing of Integrated Product Kits––FOR IMMEDIATE RELEASE–– ACEA Biosciences and Hurel® Corporation Announce Joint Marketing of Integrated Product Kits Alliance to offer customers the synergies of ACEA’s and Hurel’s two technologies functioning in concert. Integrated product kits to be marketed by both companies. San Diego, CA and North Brunswick, NJ, October 13 2014 — ACEA Biosciences (“ACEA”), a pioneer of impedance-based, label-free, real-time cell ... Read More
ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research GrantFOR IMMEDIATE RELEASE September 29, 2014   ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant   September 29, 2014, SAN DIEGO, California – ACEA Biosciences, Inc. (ACEA) has awardedJonathan Chen at Yale University the 2014 iCELLigence Research Grant for his proposal on cancer cell drug resistance studies. ACEA’s iCELLigence instrument is an impedance based real-time label-free cellular ... Read More
ACEA Biosciences Introduces the xCELLigence® RTCA CardioECR SystemFOR IMMEDIATE RELEASE September 4, 2014 ACEA Biosciences Introduces the xCELLigence® RTCA CardioECR System First Platform with Simultaneous Measurement of Cardiomyocyte Contractility and Electrophysiology   September 4, 2014, SAN DIEGO, California – In response to the need for more predictive preclinical assays for cardiac liability, ACEA Biosciences, Inc. has introduced its next generation Cardio System, the xCELLigence RTCA CardioECR System. ... Read More
Introducing the all NEW xCELLigence CardioECR System: Measure Cardiomyocyte Contractility…INTRODUCING THE ALL NEW xCELLigence CardioECR System Dual readout using impedance and field potential recording electrodes under pacing or non-pacing conditions Robust with high temporal resolution Short and long term measurements in real-time Request More InformationRead More
ACEA Biosciences Introduces the NovoCyte™ Flow CytometerACEA Biosciences Introduces the NovoCyte™ Flow Cytometer Exceptional Performance at a Low Investment Up to Fifteen Parameter Detection with Enhanced Sensitivity and Resolution FOR IMMEDIATE RELEASE April 2, 2014, SAN DIEGO, California – ACEA Biosciences, a pioneer in the development of high performance cell analysis platforms for life science research known for their xCELLigence® platform, introduces the NovoCyte flow cytometer. ... Read More
ACEA Biosciences Offers Scientists Cost Savings With the New E-Plate View PET Product LineSan Diego, CA – ACEA Biosciences, Inc. the manufacturer and developer of xCELLigence® Real-Time Cellular Analysis (RTCA) instruments, is excited to announce the global launch of the E-Plate VIEW PET product line which will bring significant cost savings to the users of the xCELLigence® system. “We are constantly striving to make advances and improvements. Built on the proven performance of ... Read More
Dr. Biao Xi, Principal Scientist at ACEA Biosciences receives the 2014 JALA Authors Choice Award for His Study on Preclinical Cardiac Safety AssessmentFOR IMMEDIATE RELEASE February 18, 2014   Dr. Biao Xi, Principal Scientist at ACEA Biosciences receives the 2014 JALA Authors Choice Award for His Study on Preclinical Cardiac Safety Assessment   SAN DIEGO, California – Announced at the Society for Laboratory Automation and Screening Conference and Exhibition in San Diego January 18-22, 2014, Dr. Biao Xi was awarded the 2014 ... Read More
Global xCELLigence User Symposium Series for 2014ACEA Biosciences, Inc. Announces its Global xCELLigence User Symposium Series for 2014 San Diego, CA – Based off of success from the xCELLigence User Symposium Series in 2013, ACEA Biosciences, Inc. announces its plan to continue their Global User Symposium Series for 2014. The xCELLigence User Symposium Series is designed to enhance scientific communication between xCELLigence users and the support ... Read More
ACEA Biosciences Is the Recipient of a SBIR Award from EPA to Develop Sensitive Cell-based Detection Systems for Environmental ToxicantsACEA Biosciences Is the Recipient of a SBIR Award from EPA to Develop Sensitive Cell-based Detection Systems for Environmental Toxicants SAN DIEGO, California– ACEA Biosciences announced today that it has been selected to receive a Small Business Innovation Research (SBIR) Award from U.S. Environmental Protection Agency (EPA) to develop sensitive cell-based detection systems for environmental toxicants. “We are very pleased ... Read More
ACEA BIOSCIENCES SELECTED FOR IRS QUALIFYING THERAPEUTIC DISCOVERY GRANTACEA Biosciences, with headquarters in San Diego, California, is pleased to announce that it has been selected to receive a grant from the Internal Revenue Service Qualifying Therapeutic Discover Project. The Qualifying Therapeutic Discover Project was created by Congress as a part of the Patient Protection and Affordable Care Act of 2010. Individual projects were selected for funding based on ... Read More
Acquisition of the xCELLigence RTCA Cardio System by FDA     San Diego – ACEA Biosciences announced today that the United States Food and Drug Administration (FDA) has acquired the xCELLigence RTCA Cardio System®. The xCELLigence RTCA Cardio System utilizes impedance readout to measure the viability and contractility of cardiomyocytes in a 96 well microtiter plate format. The system can measure the status of cardiomyocytes with millisecond time resolution and is ... Read More
ACEA Biosciences Announces that the company has developed the iPad Compatible iCELLigence SystemSan Diego, California- ACEA Biosciences, Inc (San Diego), the developer and manufacturer of the xCELLigence System, announced that the company developed  its newest product for cell-based assays, the iCELLigence System. The iCELLigence will be released to the market very soon. The iCELLigence System is composed of a plate station with a small footprint that fits inside the CO2incubator. It utilizes ... Read More
xCELLigence System Evaluated in EU Project to Replace Animal Experiments in Cosmetics Industry       ACEA and Roche’s xCELLigence RTCA System, developed and manufactured by ACEA Biosciences, Inc., and marketed by Roche, is being used in the European Union’s SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016. As of 2013, animal experiments are no longer permitted for use in toxicology testing in the cosmetic industry. ... Read More
ACEA Biosciences, Inc. Announces New Patent; Broad ClaiGranted for Cytotoxicity Profiling and Chemical Compound TestingSan Diego, California (February 7, 2011) ACEA Biosciences, Inc., a pioneer in the development of high-performance microelectronic systems for cell-based assays, diagnostics, and pharmaceutical research, is pleased to report the issuance of an important new U. S. Patent for chemical compound screening, with important applications in the development of new pharmaceutical products. Testing and profiling of these candidate compounds by ... Read More
Quantitative Assessment of Clostridium Difficile Toxin by Real Time Cell AnalysisQuantitative Assessment of Clostridium Difficile Toxin by Real Time Cell Analysis In a recent paper published in the Journal of Clinical Microbiology (J Clin Micro, 48: 4129-4134, Nov., 2010) the xCELLigence RTCA System, developed by San Diego-based ACEA Biosciences, was used to assess infections of patients with Clostridium difficile. The label-free, real-time RTCA System was developed by ACEA for monitoring ... Read More
Vivo Biosciences, ACEA Biosciences, and Roche to develop new xCELLigence System assays for stem cell and cancer researchPenzberg, Germany, October 6, 2010 ACEA Biosciences Inc. (San Diego, CA) and Vivo Biosciences Inc. (Birmingham, AL, US) announced that they have entered into a collaboration for the further development of label-free and real-time cell based assays for the xCELLigence System, which is co-developed by Roche (SIX: RO, ROG; OTCQX: RHHBY) and ACEA and marketed by Roche Applied Science. The ... Read More
Roche’s new RTCA Cardio Instrument for label-free functional cardiomyocyte toxicity testingPenzberg, Germany , September 28, 2010 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA Cardio Instrument is a medium- throughput cell-analyzer for the dynamic monitoring of cardiac beating and cellular events by impedance-readings. It features a unique detection rate and frequency measurement as ... Read More
Cellular Dynamics International, ACEA Biosciences, and Roche Applied Sciences Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence SystemPenzberg, Germany , September 16, 2010 Cellular Dynamics International, ACEA Biosciences, and Roche Applied Sciences Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System. Cellular Dynamics International (CDI) announced today their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process. The partnership combines CDI’s induced pluripotent stem cell (iPSC)-derived ... Read More
The xCELLigence RTCA Cardio SystemCellular Dynamics International (CDI) announced today their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process. The partnership combines CDI’s induced pluripotent stem cell (iPSC)-derived heart cells, iCell Cardiomyocytes, with the xCELLigence RTCA System. The xCELLigence System is developed by ACEA and Roche Applied Science (SIX: RO, ROG; OTCQX: ... Read More
ACEA Biosciences, Inc., announces a major breakthrough in cardiotoxicity testing and limited-time free-access to customersSan Diego, CA June 18, 2010 ACEA Biosciences, Inc., with headquarters in San Diego, CA, is pleased to announce the early availability of its unique RTCA Cardiotoxicity testing system as a limited-time, no fee service for testing chemical compounds for cardiotoxicity. This advanced microelectronic technology, which monitors the beating, stem-cell derived and other cardiomyocytes, was recently presented on June 16th, ... Read More
RTCA Cardiotoxicity testing systemACEA Biosciences, Inc., with headquarters in San Diego, CA, is pleased to announce the early availability of its unique RTCA Cardiotoxicity testing system as a limited-time, no fee service for testing chemical compounds for cardiotoxicity. This advanced microelectronic technology, which monitors the beating, stem-cell derived and other cardiomyocytes, was recently presented on June 16th, 2010, at the World Pharmaceutical Congress, ... Read More
the Early Detection of Hepatic CytotoxicityReducing Animal Testing: Real-time Cell Analysis with Roche´s xCELLigence System for the Early Detection of Hepatic Cytotoxicity The 3Rs concept of reducing, refining and replacing animal experimentation was developed by W.M.S. Russell and R.L. Burch in their book “The Principles of Humane Experimental Technique” more than 50 years ago. Today, early identification of toxic compounds using cell-based in vitro assays ... Read More